| Completed | A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma Multiple Myeloma | Phase 1 | 2021-02-24 |
| Completed | A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/ Multiple Myeloma | Phase 1 | 2020-08-18 |
| Completed | A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Lymphoma Non-Hodgkin, Agressive Lymphoma, Diffuse-large B-cell Lymphoma (DLBCL) | Phase 1 | 2020-05-21 |
| Completed | A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymp Lymphoma, Non-Hodgkin, Lymphoma, Lymphoma, B-Cell | Phase 2 | 2018-11-29 |
| Completed | Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin, Lymphoma, B-Cell | Phase 2 | 2018-07-27 |
| Terminated | Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product Non Hodgkin Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia | — | 2018-02-19 |
| Completed | Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myel Multiple Myeloma | Phase 1 / Phase 2 | 2018-02-01 |
| Recruiting | Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Le Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic | Phase 1 / Phase 2 | 2017-11-27 |
| Completed | Long-Term Follow-up Study for Patients Previously Treated With JCAR015 Acute Lymphoblastic Leukemia | — | 2016-08-30 |
| Completed | Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma | Phase 1 | 2016-01-06 |
| Terminated | Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) Acute Lymphoblastic Leukemia | Phase 2 | 2015-08-21 |
| Available | Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol Lymphoma, Large B-Cell, Diffuse | — | — |